Brovana

(arformoterol tartrate) Inhalation Solution

  • Prescribing Information
  • Professional Resources
  • Contact Us
  • Patient Site
  • About Brovana
  • About PIFR
  • Clinical Data
  • Patient Profiles
  • Risk Information
  • Clinical Data
  • Lung Function
  • Symptom Relief
  • Exacerbations
  • Safety/Adverse Events
  • Duration
  • Nighttime
  • Rescue Medications
  • Tolerance
  • Dyspnea

The role of PIFR

What is PIFR and why consider it in COPD patients?

Learn More

Sunovion ProFile

Resources for U.S. Healthcare Professionals

Sign up now for professional resources

Home > Clinical Data

  • smallmediumlarge
  • Share
  • Print

Clinical Data

The clinical and safety data presented in this section will help you understand how BROVANA, a nebulized  LABA, may benefit patients with moderate to very severe COPD.

COPD patients experienced:

  • Improved lung function within minutes
  • Improved patient-reported overall COPD symptoms
  • Fewer reported exacerbations
  • A proven safety profile
  • A 12-hour bronchodilation/duration with every dose

 

 

Please see Important Safety Information and full Prescribing Information for BROVANA, including Boxed Warning.

Indication

BROVANA is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.

Important Safety Information

WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including arformoterol, the active ingredient in BROVANA (see WARNINGS). The safety and efficacy of BROVANA in patients with asthma have not been established. All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS).

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.

BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

For additional information, please see the full Prescribing Information and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  • Professional Resources
  • Contact Us
  • Terms of Use
  • Privacy Statement
  • Medical Disclaimer
  • Site Map
  • Unsubscribe

BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. ©2011 Sunovion Pharmaceuticals Inc. All rights reserved. 07/11 BRO093-11.